Business Wire

NY-CLINIQUE

2.2.2024 15:01:27 CET | Business Wire | Press release

Share
Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center

Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-thinking research in dermatology, exploring the biological underpinnings of how skin ages, skin allergies and inflammatory or eczematous skin conditions, including eczema (or atopic dermatitis) and contact dermatitis. Rooted in a shared mission to conduct dermatological research that improves patients’ lives, the partnership will focus on applicable scientific discovery and leading-edge innovation to modernize allergy science in order to identify innovative solutions for these skin conditions.

Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions. The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin. By investigating healthy skin, along with the skin of those with atopic dermatitis and other allergic skin disorders, the researchers may learn how to significantly slow the visible signs of aging in all people as well as in patients with eczema, who show signs of premature or accelerated aging. Insights from this research aim to spur advances in the field of dermatology and skin health. Additionally, they will inform and inspire Clinique in future product innovation to offer further solutions for people with allergic or sensitive skin.

“As a brand that has offered dermatologist guided solutions and allergy tested solutions since its inception, Clinique is proud to partner with the renowned institution of Icahn Mount Sinai and its team of physician-scientists, led by a world-renowned expert in allergic and inflammatory skin diseases, Dr. Emma Guttman. We are inspired by the team’s dedication to the research and future discoveries of allergic skin and its life impact, including aging. We are energized by our mutual commitment and steadfast belief that great skin can be created and maintained for all. I am confident that this first-of-its-kind partnership will enable groundbreaking research by leading physician-scientists dedicated to advancing allergy science,” Michelle Freyre, President, Global Brands, Clinique.

Dr. Emma Guttman, MD, PhD, Waldman Professor and System Chair, Department of Dermatology at the Icahn School of Medicine, a trailblazer in dermatologic science, has dedicated her career to bridging science with practice intended to improve patients’ lives. Her work has led to novel therapeutic targets for patients suffering from inflammatory skin conditions. Drawing inspiration from her personal and family history of eczema and other allergic conditions, Dr. Guttman has made it her mission to alleviate sensitive skin.

“Years of chronic inflamed skin plays a role in premature aging. Extensive research has helped us understand the molecular map of skin conditions associated with allergy such as eczema and contact dermatitis, and we’re now at a pivotal point in addressing these conditions and more. With Clinique’s support, we will continue to actively explore targeted approaches to reversing eczematous and allergic skin conditions with the goal of creating and sustaining healthy skin. In turn, we want to use this understanding to address and prevent the process of age-related inflammation or ‘inflammaging’ in the first place,” says Dr. Guttman, who also directs the Center of Excellence in Eczema at Mount Sinai and the Laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai.

The laboratory of Inflammatory Skin Diseases at Icahn Mount Sinai has a major focus on atopic dermatitis, contact dermatitis, alopecia areata, and other inflammatory skin diseases. It has made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis, opening the door to new therapeutics. Dr. Guttman’s lab developed the only comprehensive molecular maps of atopic dermatitis, defining skin differentiation and immune-circuits characterizing this disease across phenotypes and ages. This work on atopic dermatitis/eczema has contributed directly to many of the recently developed treatments for this disease, earning Dr. Guttman and her lab a unique place as being a top leader in dermatology and immunology worldwide.

Clinique has a long-standing history of partnering with dermatologists, including its Founding Dermatologist, Norman Orentreich, MD, and incorporating patients’ insights in its innovation since 1968. His children, Catherine Orentreich, MD, and David Orentreich, MD, the brand’s Guiding Dermatologists, continue their father’s legacy for Clinique. Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.

In this meaningful mission, Clinique has made a philanthropic commitment of $5 million over seven years for the advancement and evolution of allergy science through the partnership and founding of the Mount Sinai-Clinique Healthy Skin Dermatology Center. The funds will be used to recruit the best and brightest physicians and scientists, and provide resources for the most advanced equipment, clinical and laboratory space, and key support staff. The studies conducted by the Mount Sinai-Clinique Healthy Skin Dermatology Center will include all ages, genders, races and ethnicities, and will also investigate the effects of factors such as diet, exercise, and stress on the skin of healthy people. Mount Sinai predicts that with Clinique’s support, critical breakthroughs will be fast-tracked, from the earliest stages of the multiyear partnership.

About Mount Sinai Health System:
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.

About Clinique:
In 1968, a beauty editor asked a leading New York City dermatologist, “Can great skin be created?” The answer: yes. And with that yes, Clinique was born. Today Clinique is the #1 Dermatologist Brand in Skincare in the US* and #1 Dermatologist Brand in Makeup in the US**, offering its dermatologist guided, allergy tested solutions for remarkable skin results. The brand is sold in 107 markets worldwide. Clinique’s clinical solutions are informed by years of research, working with dermatologists, scientists, and ophthalmologists. All Clinique formulas are designed to deliver powerful efficacy with rigorous safety —clinically proven, allergy tested, and 100% fragrance free.

*Source: Circana, U.S. Prestige Beauty Total Measured Market, Skincare Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023
**Source: Circana, U.S. Prestige Beauty Total Measured Market, Makeup Unit Sales, Derm Brand Attribute, 12 Months Ending December 2023

Derm Brand is defined as a brand that was founded or developed by a dermatologist and/or is dermatologist recommended.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240202954316/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 00:05:00 CEST | Press release

Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibodyBoth investigational therapies are being evaluated in ongoing Phase 3 programsIncyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 CET / 2:30 – 4:00 p.m. ET Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs

DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future18.10.2026 20:35:00 CEST | Press release

The Digital Cooperation Organization (DCO) launched the second edition of the Digital Prosperity Awards (DPA), opening applications and nominations for eligible public-sector, private-sector and civil-society digital solutions across Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261018682401/en/ DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future (Photo: AETOSWire) The Awards recognize technology-driven solutions, initiatives and contributions delivering measurable socioeconomic impact, accelerating digital transformation and advancing an inclusive, sustainable and prosperous digital economy. The inaugural edition honored seven winners in February 2025. Ms. Deemah AlYahya, Secretary-General of the DCO, said: “A prosperous digital future is taking shape today through the vision, commitment and creativity of governments, innovators, organization

Andersen Global styrker sin skatterådgivning til privatkunder med KTA Tax17.10.2026 07:43:00 CEST | Pressemeddelelse

Andersen Global udvider sine skatterådgivningskompetencer inden for private client-området gennem en samarbejdsaftale med KTA Tax, en skattevirksomhed med base i Dublin, der har rådgivet enkeltpersoner og familier i næsten tre årtier. KTA Tax har rådgivet privatkunder og deres familier siden 1997 og forener den personlige tilgang fra et specialiseret rådgivningsfirma med indgående teknisk viden om irsk skatteret. Firmaets ydelser omfatter transaktions- og skatteplanlægning, generationsskifteplanlægning, investeringer og pensioner, internationale skatteforhold, sager hos skattemyndighederne, beskatning af løn og personalegoder samt årlig håndtering af personlige skatteforpligtelser. "Vi har hele tiden haft fokus på én ting: at yde klar og grundig skatterådgivning, der tager højde for vores kunder og deres familiers individuelle forhold," udtalte Lisa Cantillon, administrerende direktør for KTA Tax. "Samarbejdet med Andersen Global er et vigtigt skridt for KTA Tax. Det giver os mulighed

Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World16.10.2026 16:00:00 CEST | Press release

Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016490320/en/ Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World (Photo: AETOSWire) It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment. The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating oppor

TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal16.10.2026 16:00:00 CEST | Press release

Plain-English mobile tests now run on real Android and iOS devices in the TestMu AI cloud from any Mac, Windows, or Linux machine, with a live view of the device on the developer's laptop TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device. Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams: Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye